Provectus Biopharma (PVCT) Reports Complete Enrollment of Phase 1B Trial of PV-10 in Combination with Merck's (MRK) Keytruda
Tweet Send to a Friend
Provectus today announced the completion of enrollment of 24 patients with metastatic melanoma into the Phase 1b portion of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
